(Q38020236)

English

A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain

scientific article published on 21 June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 August 2017

A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain (English)

1 reference

Europe PubMed Central

27 August 2017

musculoskeletal pain

0 references

neuropathic pain

0 references

0 references

0 references

0 references

chronic neuropathic pain

0 references

pain management

0 references

3

object named as

Robert Taylor

1 reference

Europe PubMed Central

27 August 2017

author name string

Joseph V Pergolizzi

1

1 reference

Europe PubMed Central

27 August 2017

Robert B Raffa

2

1 reference

Europe PubMed Central

27 August 2017

Gabriel Rodriguez

4

1 reference

Europe PubMed Central

27 August 2017

Srinivas Nalamachu

5

1 reference

Europe PubMed Central

27 August 2017

Paul Langley

6

1 reference

Europe PubMed Central

27 August 2017

publication date

21 June 2012

1 reference

Europe PubMed Central

27 August 2017

1 reference

Europe PubMed Central

27 August 2017

13

1 reference

Europe PubMed Central

27 August 2017

239-252

1 reference

Europe PubMed Central

27 August 2017

3

1 reference

Europe PubMed Central

27 August 2017

Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Descending control of pain

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine: clinical pharmacokinetics and drug interactions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine: a review of its pharmacology and use in chronic pain management

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Acute and chronic pain management in fibromyalgia: updates on pharmacotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine in the treatment of major psychiatric and neuropathic disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Can we conquer pain?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Advances in the management of diabetic peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

The prevalence and characteristics of fibromyalgia in the general population.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Classification, epidemiology, and natural history of fibromyalgia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Patient perspectives on the impact of fibromyalgia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Predictors of pain medication selection among patients diagnosed with fibromyalgia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

The significance of dysfunctions of the sleeping/waking brain to the pathogenesis and treatment of fibromyalgia syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Management of fibromyalgia syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Pharmacotherapy of fibromyalgia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

A review of SSRIs and SNRIs in neuropathic pain

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Effect of duloxetine in patients with fibromyalgia: tiredness subgroups

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Early improvement in pain predicts pain response at endpoint in patients with fibromyalgia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Pain response profile of patients with fibromyalgia treated with duloxetine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Pharmacological modulation of movement-evoked pain in a rat model of osteoarthritis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine in treatment of refractory chronic tennis elbow: two case reports

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Answers to the most common questions about the hepatic safety profile of duloxetine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Weight change with long-term duloxetine use in chronic painful conditions: an analysis of 16 clinical studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Continuation treatment of major depressive disorder: is there a case for duloxetine?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Sexual side-effects of contemporary antidepressants: review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Antidepressants and sexual dysfunction.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine and suicide attempts: a possible relation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Safety of newer antidepressants in pregnancy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine contributing to a successful multimodal treatment program for peripheral femoral neuropathy and comorbid 'reactive depression' in an adolescent

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine for the management of diabetic peripheral neuropathic pain: response profile

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Efficacy and safety of duloxetine in patients with chronic low back pain

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

A single-blind, placebo run-in study of duloxetine for activity-limiting osteoarthritis pain

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Duloxetine in the treatment of osteoarthritis knee pain

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Efficacy of Duloxetine on Cognition, Depression, and Pain in Elderly Patients With Major Depressive Disorder: An 8-Week, Double-Blind, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-2500.2012.00578.X

21 January 2018

Identifiers

10.1111/J.1533-2500.2012.00578.X

1 reference

Europe PubMed Central

27 August 2017

1 reference

Europe PubMed Central

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38020236&oldid=1737606729"